Acenta Discovery provides chemistry based drug discovery products and services for large pharmaceutical and research firms, as well as small and middle-market biotechnology firms. Since being founded in November 2002 by an accomplished scientist with two drugs currently in the clinic who was trained at Harvard under Dr. Elias J. Corey (Nobel Prize and Priestley Medal Recipient) in partnership with an experienced executive and entrepreneur who led a division of a multi-national chemical company acquired by Zeneca, Acenta has shown a steady rate of growth in new client contracts, profitability and innovations through its on-going research supported by federal grant funding.
Acenta produces value for partners by providing them cutting edge medicinal chemistry solutions on a fee-for-service basis, as well as access to the firm's growing pipeline of intellectual property in the fields of cancer and neurosciences. The company offers both service and product solutions including Quick-HitTM compound libraries to initiate client and partner research programs, focused chemistry services (computational chemistry, synthetic chemistry, chemistry consulting), and composition of matter that may be accessed through licensing or strategic development
